ReviewCirculation2011
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.
Review in Circulation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05711719 (Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction), which is not on this map. Cited by 298 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Who cites it
298 citing papers in PubMed, 5 syntheses or guidelines pooled it, 581 citations in OpenAlex.
- Efficacy and safety of vericiguat across the spectrum of heart failure: a systematic review and updated meta‑analysis of randomized controlled trials.European journal of clinical pharmacology · 2026Pooled it
- Efficacy and safety of soluble guanylate cyclase stimulators or activators for chronic kidney disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods.Frontiers in pharmacology · 2025Pooled it
- Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA.Frontiers in endocrinology · 2024Pooled it
- Pooled it
- The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study.The American journal of cardiology · 2026Trial
- Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.European heart journal · 2022Trial
- Body mass-normalized moderate dose of dietary nitrate intake improves endothelial function and walking capacity in patients with peripheral artery disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Trial
- Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism.Nitric oxide : biology and chemistry · 2020Trial
- A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.Arthritis research & therapy · 2019Trial
- Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.The European respiratory journal · 2019Trial
- Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.Heart (British Cardiac Society) · 2017Trial
- Sex differences in the developmental programming of cardiovascular and renal risk across the lifespan.American journal of physiology. Renal physiology · 2026Review
- NO modulates human airway smooth muscle function by altering glucose-6-phosphate dehydrogenase effects on sGC function in asthma.Redox biology · 2026Article
- Article
- The NO-cGMP signaling pathway and depression: mechanisms and therapeutic prospects.Molecular biology reports · 2026Review
- Carbon dioxide is a triple vasodilator.Cardiovascular research · 2026Article
- Article
- Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.BMC cardiovascular disorders · 2026Observational
- Vericiguat Attenuates Vascular Calcification by Cyclic Guanosine Monophosphate-Protein Kinase G Pathway Mediated Suppression of Matrix Metalloproteinase 10.Journal of the American Heart Association · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.